India's Venus Remedies gains on marketing nod for two drugs in Europe
** Shares of Venus Remedies VENR.NS rise as much as 4.18%
to 425 rupees; stock last up 3.2%
** Pharma company receives new marketing authorizations for
two drugs in Malta, Europe
** Approvals to help in expanding global reach, says VENR
** Trading volume is 123,997 shares as of 12:05 p.m. IST,
1.1x the 30-day avg - LSEG data
** VENR shares up 4.4% in January so far, after jumping
124.32% in 2023
(Reporting by Bharath Rajeswaran in Bengaluru)
((bharath.rajeswaran@thomsonreuters.com; +91 9769003463;))
Recent news on Venus Remedies
See all newsBrief: Venus Remedies Sept-Quarter Consol Net Profit 256.5 Million Rupees
Brief: Venus Remedies Secured Five Marketing Authorisations Across Kazakhstan, Peru, Kuwait And Argentina
India's Venus Remedies rises after quarterly profit more than doubles
Brief: Venus Remedies June-Quarter Consol Net Profit 229.7 Million Rupees
India raises price cap on cancer drugs to tackle shortage